Emergent BioSolutions Inc. (EBS) › Total LiabilitiesEmergent BioSolutions Inc. (EBS) — Total LiabilitiesAnnual figures by period end, from SEC filings.2010-12-31: $126.76M2011-12-31: $130.14M2012-12-31: $122.10M2013-12-31: $137.47M2014-12-31: $385.49M2015-12-31: $377.47M2016-12-31: $373.91M2017-12-31: $157.90M2018-12-31: $1.22B2019-12-31: $1.24B2020-12-31: $1.44B2021-12-31: $1.35B2022-12-31: $1.78B2023-12-31: $1.17B2024-12-31: $906.90M2025-12-31: $796.00M$796.00M2010-12-31Total Liabilities (USD)2025-12-31Period endedTotal LiabilitiesChange YoYSource filing2025-12-31$796.00M-12.2%2026-02-27Balance as of period end2024-12-31$906.90M-22.7%2026-02-27Balance as of period end2023-12-31$1.17B-34.0%2025-03-04Balance as of period end2022-12-31$1.78B+32.1%2024-03-08Balance as of period end2021-12-31$1.35B-6.3%2023-12-11Balance as of period end2020-12-31$1.44B+15.9%2022-02-25Balance as of period end2019-12-31$1.24B+1.7%2021-02-19Balance as of period end2018-12-31$1.22B+671.7%2020-02-25Balance as of period end2017-12-31$157.90M-57.8%2019-02-22Balance as of period end2016-12-31$373.91M-0.9%2018-02-23Balance as of period end2015-12-31$377.47M-2.1%2017-02-28Balance as of period end2014-12-31$385.49M+180.4%2016-02-29Balance as of period end2013-12-31$137.47M+12.6%2015-03-09Balance as of period end2012-12-31$122.10M-6.2%2014-03-10Balance as of period end2011-12-31$130.14M+2.7%2013-03-08Balance as of period end2010-12-31$126.76M—2012-03-09Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)